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ORIGINAL RESEARCH

Machine Learning Identiﬁes Clinical
and Genetic Factors Associated
With Anthracycline Cardiotoxicity in
Pediatric Cancer Survivors
Marie-A Chaix, MD, MSC,a,b Neha Parmar, BSC,a Caroline Kinnear, MSC,a Myriam Lafreniere-Roula, PHD,c
Oyediran Akinrinade, PHD,a Roderick Yao, BCS,a Anastasia Miron, BAH,a Emily Lam, MSC,a Guoliang Meng, PHD,d
Anne Christie, MSC,a Ashok Kumar Manickaraj, PHD,1,a Stacey Marjerrison, MD,e Rejane Dillenburg, MD, MSC,e
Mylène Bassal, MDCM,f Jane Lougheed, MD,f Shayna Zelcer, MD,g Herschel Rosenberg, MD,g David Hodgson, MD,h
Leonard Sender, MD,i Paul Kantor, MD,j Cedric Manlhiot, PHD,k James Ellis, PHD,d,l Luc Mertens, MD,m
Paul C. Nathan, MD,m Seema Mital, MDa,m

ABSTRACT
BACKGROUND Despite known clinical risk factors, predicting anthracycline cardiotoxicity remains challenging.
OBJECTIVES This study sought to develop a clinical and genetic risk prediction model for anthracycline cardiotoxicity
in childhood cancer survivors.
METHODS We performed exome sequencing in 289 childhood cancer survivors at least 3 years from anthracycline
exposure. In a nested case-control design, 183 case patients with reduced left ventricular ejection fraction despite lowdose doxorubicin (#250 mg/m2), and 106 control patients with preserved left ventricular ejection fraction despite
doxorubicin >250 mg/m2 were selected as extreme phenotypes. Rare/low-frequency variants were collapsed to identify
genes differentially enriched for variants between case patients and control patients. The expression levels of 5 topranked genes were evaluated in human induced pluripotent stem cell–derived cardiomyocytes, and variant enrichment
was conﬁrmed in a replication cohort. Using random forest, a risk prediction model that included genetic and clinical
predictors was developed.
RESULTS Thirty-one genes were differentially enriched for variants between case patients and control patients (p <
0.001). Only 42.6% case patients harbored a variant in these genes compared to 89.6% control patients (odds ratio:
0.09; 95% conﬁdence interval: 0.04 to 0.17; p ¼ 3.98  10–15). A risk prediction model for cardiotoxicity that included
clinical and genetic factors had a higher prediction accuracy and lower misclassiﬁcation rate compared to the clinical-only
model. In vitro inhibition of gene-associated pathways (PI3KR2, ZNF827) provided protection from cardiotoxicity in
cardiomyocytes.
CONCLUSIONS Our study identiﬁed variants in cardiac injury pathway genes that protect against cardiotoxicity and
informed the development of a prediction model for delayed anthracycline cardiotoxicity, and it also provided new
targets in autophagy genes for the development of cardio-protective drugs. (Preventing Cardiac Sequelae in Pediatric
Cancer Survivors [PCS2]; NCT01805778) (J Am Coll Cardiol CardioOnc 2020;2:690–706) © 2020 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nthracycline chemotherapy, used in almost

multicenter, prospective, longitudinal cohort

ABBREVIATIONS

50% of pediatric cancers, is a major cause of

study involving 6 North American sites (12).

AND ACRONYMS

cardiac

survivors.

Patients followed up in survivor clinics,

Anthracycline cardiotoxicity can manifest as left ven-

morbidity

in

cancer

age <18 years at the time of anthracycline

tricular (LV) dysfunction and heart failure (1). Sixty

exposure, and at least 3 years from their last

percent of childhood cancer survivors develop echo-

anthracycline dose were eligible. Patients

cardiographic cardiac dysfunction, and 10% develop

with congenital heart disease were excluded.

symptomatic cardiomyopathy up to decades after

Clinical data were collected from medical

chemotherapy (delayed toxicity) (2). Clinical factors

records. The anthracycline cumulative dose

associated with cardiotoxicity include younger age

was measured in doxorubicin (DOX) equiva-

at exposure, cumulative anthracycline dose, radia-

2

lents (mg/m ), that is, daunorubicin total

tion therapy involving the heart, female sex, Afri-

dose multiplied by 0.5, epirubicin total dose

can ethnicity, and pre-existing cardiac dysfunction

multiplied by 0.6, idarubicin total dose

(3,4). However, clinical factors have limited ability

multiplied by 5, and mitoxantrone total dose

to predict patients who are at risk for cardiotoxicity

multiplied by 4 (13). LV ejection fraction

(5).

(LVEF)

was

measured

by

2-dimensional

AUC = area under the curve
CI = conﬁdence interval
DMSO = dimethyl sulfoxide
DOX = doxorubicin
GSEA = gene set enrichment
analysis

H2AX = H2A family member X
hiPSC-CM = human induced
pluripotent stem cell–derived
cardiomyocyte

IC50 = half-maximal inhibitory
concentration

LV = left ventricular
LVEF = left ventricular

Candidate single-nucleotide variant (SNV) and

echocardiography at enrollment and at 1 and

ejection fraction

genome-wide association studies (6–9) have identi-

2 years of follow-up and analyzed at an

MAF = minor allele frequency

ﬁed an association with cardiotoxicity of common

independent core laboratory (12). All partici-

mRNA = messenger RNA

exonic and intronic variants in genes involved in

pants provided a blood sample at enrollment.

anthracycline transport and metabolism, oxidative

Written informed consent was obtained from

stress, DNA repair, iron metabolism, nicotinamide

participants/parents/legal guardians, and the

Project

adenine

protocol

RF = random forest

dinucleotide

phosphate complex, topo-

was

approved

by

institutional

OR = odds ratio
PGP = Personal Genome

isomerase 2 b expression, and sarcomeric genes (10).

Research Ethics Boards. Extreme phenotypes

These together explain only a small proportion of

were selected in a nested case-control design

cases and do not consider the contribution of rare

from the overall cohort. Cases included pa-

SNV = single-nucleotide

variants that can have larger effects on gene func-

tients who received low cumulative anthra-

variant

SKAT = sequence kernel
association test

tion (2,11). The objective of our study was to

cycline dose (#250 mg/m 2) but developed either: 1)

identify the contribution of rare and low-frequency

clinically

SNVs

late

of #50% or >10% LVEF decline to #55% from a pre-

anthracycline cardiotoxicity, to validate the func-

vious echocardiogram during follow-up; or 2) low

tional role of the affected genes, and to generate an

LVEF of #55% based on American Society of Echo-

integrated risk prediction model for anthracycline

cardiography guidelines (14,15). Control patients were

cardiotoxicity that combines clinical and genetic

patients with preserved cardiac function (LVEF of

factors (Central Illustration).

>55%) despite high dose anthracycline (>250 mg/m 2).

METHODS

WHOLE-EXOME SEQUENCING. Whole-exome sequencing

that

inﬂuence

the

susceptibility

to

deﬁned

cardiotoxicity,

that

is,

LVEF

was performed (average: 100 depth) by using the
STUDY

COHORT. The

PCS2

(Preventing

Cardiac

Illumina (San Diego, California) HiSeq X platform.

Sequelae in Pediatric Cancer Survivors) study is a

High quality paired-end reads (2  150 bp) were
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Angeles, California, USA; kDepartment of Pediatrics, Johns Hopkins Medical Center, Baltimore, Maryland, USA; lDepartment of
Molecular Genetics, University of Toronto, Ontario, Canada; and the
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C E N T R A L IL L U ST R A T I O N An Integrated Precision Approach to Predict Anthracycline
Cardiotoxicity

Chaix, M.-A. et al. J Am Coll Cardiol CardioOnc. 2020;2(5):690–706.

Whole-exome sequencing data from 289 pediatric cancer survivors with extreme phenotypes identiﬁed a higher burden of rare variants in
control patients compared to case patients in 31 biologically relevant genes. The top-ranked genes were functionally evaluated in human
induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) and variant enrichment was conﬁrmed in a replication cohort. Targeted
pathway inhibitors were more effective at reducing anthracycline-induced injury than dexrazoxane. Using random forest, clinical and genetic
predictors were integrated into a prediction model for anthracycline cardiotoxicity.

mapped to the human genome reference sequence

(Catalogue of Somatic Mutations in Cancer) database

(hg19, National Center for Biotechnology Informa-

were excluded (18,19).

tion, Bethesda, Maryland) by using the bwa mem

VARIANT BURDEN ANALYSIS USING GENE-COLLAPSING

aligner, version 0.7.8 (Wellcome Trust Sanger Insti-

METHODS. All rare and low-frequency variants were

tute, Cambridge, United Kingdom), and variants

collapsed within genes to generate a gene-level

were called using the Genome Analysis Toolkit,

variant score in every sample. Three gene-based as-

version 3.8.0 (16). Variants passing the default

sociation analyses were performed: 1) burden com-

Genome Analysis Toolkit (Broad Institute, Cam-

bined multivariate and collapsing, which assumes

bridge, Massachusetts) variant caller quality metrics

that all functional variants in the gene have effects in

were

4.3

the same direction (20); 2) sequence kernel associa-

National

tion test (SKAT), a variance-component test that as-

Bethesda,

sumes that a variant can have either a positive or a

Maryland). Quality control ﬁlters were applied to

negative effect (21); and 3) SKAT-optimized, a com-

identify SNVs

top

bination of these 2 methods (22). The association

principal components were calculated using single-

analyses were adjusted for sex, cancer diagnosis, age

nucleotide polymorphisms common to both the

at the start of anthracycline, use of dexrazoxane,

HapMap (Catalogue of Somatic Mutations in Cancer,

chest radiation, duration of follow-up from ﬁrst

annotated

(International
Human

by

using

Haplotype

Genome

snpEff,

Map

Research

(17).

To map

version

Project,

Institute,

ancestry, the

Wellcome Trust Sanger Institute, Cambridge, United

anthracycline dose, and the ﬁrst 2 principal compo-

Kingdom) and PCS2 cohort with minor allele fre-

nents inferring ethnicity. Genes with an association p

quency (MAF) of >0.01 and Hardy-Weinberg equi-

value of <0.001 by at least 2 gene-collapsing methods

librium p > 1.00  10 –6 . Common (MAF: >0.05) and

and genes in biologically relevant pathways with an

variants associated with cancer in the COSMIC

association of p < 0.001 by at least 1 method were
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included in downstream analysis and model devel-

Clara, California) that contain gold microelectrode

opment. Genome-wide signiﬁcance was deﬁned as a

arrays fused to the bottom of each well (coated with

nominal p < 2.87  106 by using Bonferroni correc-

ﬁbronectin). Experiments were performed on day 34,

tion based on 17,382 genes. Results are presented as

when they exhibit a more mature phenotype, with

odds ratio (ORs) with 95% conﬁdence intervals (CIs).

regular contractility, stable electrical signals, and

Genes signiﬁcantly associated with case/control sta-

sarcomeric organization. CMs were treated with 0.01,

tus were further analyzed after adjustment for cu-

0.1, and 0.5 m mol/l of doxorubicin hydrochloride

mulative anthracycline dose and use of concomitant

(DOX) (product no. D1515, Sigma-Aldrich, St. Louis,

cardiotoxic drugs by using logistic regression.

Missouri) on day 34 for 24 h. Cell index derived from

PATHWAY ANALYSIS. Prioritized genes were included

in a gene network analysis using GeneMania (23).
Gene set enrichment analysis (GSEA) was performed
by using the Java implementation of GSEA version 3.0
(Broad institute, Inc., Massachusetts Institute of
Technology, Cambridge, Massachusetts) (24). The
Fisher exact test p value comparing the enrichment of
variants between case patients and control patients
was used for gene ranking. GSEA was run using Gene
Ontology pathways, version 6, with 1,000 permutations. A p value of <0.001 was considered signiﬁcant.
Prioritized genes were functionally evaluated in
human cardiomyocytes.
FUNCTIONAL

change in impedance values, a measure of contractility and viability, was recorded and analyzed by
using the xCELLigence RTCA Cardio system (Agilent,
Santa Clara, California) (27).
M e t a b o l i c a c t i v i t y a n d c e l l v i a b i l i t y . hiPSC-CMs
at day 16 were seeded (40,000 cells/well) in 96-well
plates, treated with DOX on day 34, and incubated
with a 1:100 dilution of PrestoBlue Cell Viability Reagent (Life Technologies, no. A13261, Carlsbad, California) a resazurin-based assay that uses the reducing
environment of cells to measure metabolic activity
and cell viability, for 1.5 h at 37  C. The average ﬂuorescence values at 560/590 nm (excitation/emission)
of the empty control wells were subtracted from that

EVALUATION

GENES. D i f f e r e n t i a t i o n

OF

of

PRIORITIZED

human

induced

of the experimental wells to provide relative ﬂuorescence units.

p l u r i p o t e n t s t e m c e l l s i n t o c a r d i o m y o c y t e s . To

Immunoﬂuorescence for DNA damage markers. hiPSC-

ascertain the functional role of the prioritized genes

CMs at day 16 were seeded in black 24-well glass

in cardiotoxicity, human induced pluripotent stem

bottom plates for confocal microscopy and treated

were

with DOX for 24 h on day 34. After ﬁxation with 4%

generated. Two previously published hiPSC cell

paraformaldehyde, the cells were incubated with

cell–derived

cardiomyocytes

(hiPSC-CMs)

lines (PGP17_11 and PGP14_26), reprogrammed from

1:1,000 monoclonal mouse g -H2A family member X

lymphocytes taken from 2 healthy male donors in

(H2AX) (phospho S139) (Abcam, ab26350, Cambridge,

the Personal Genome Project (PGP) were used (25).

United Kingdom) for 24 h to measure double-

We conﬁrmed the absence of pathogenic or likely

stranded DNA breaks and incubated with 1:100

pathogenic SNVs (based on American College of

Alexa Fluor 488 conjugated secondary antibody

Medical Genetics criteria) in known cardiotoxicity

(Thermo Fisher Scientiﬁc, A21042, Waltham, Massa-

genes and genes identiﬁed in our study in the

chusetts). Images were taken on WaveFX-X1 spinning

ﬁles

disk confocal system (Quorum Technologies Inc.,

downloaded from the PGP-Canada website (26). The

Guelph, Canada) by using a Hamamatsu (Hamamatsu

STEMdiff

Kit

City, Japan) C9100-13 electron multiplying charge

(STEMCELL Technologies, Vancouver, Canada) was

coupled device camera. Volocity software (Perkin

used to differentiate hiPSCs into CMs in accordance

Elmer, Waltham, Massachusetts) was used for the

donors

with

through

our

interrogation

Cardiomyocyte

previously

of

vcf

Differentiation

published

differentiation

quantiﬁcation of nuclear g -H2AX foci.

protocol (26). At day 16, cells were dissociated,

M e s s e n g e r R N A e x p r e s s i o n i n h i P S C - C M s . Quan-

reseeded,

STEMdiff

titative reverse-transcription polymerase chain reac-

Cardiomyocyte Maintenance medium (STEMCELL

tion (RT-qPCR) was performed on hiPSC-CMs to

Technologies), which was replaced every 2 days, in

measure change in messenger RNA (mRNA) expres-

80% relative humidity levels and 5% CO2 levels, to

sion of selected genes following 24 h of DOX exposure.

generate beating CMs.

Total RNA was extracted from the hiPSC-CMs by using

and

maintained

in

the TRIzol reagent phenol-chloroform extraction
C e l l c o n t r a c t i l i t y . hiPSC-CMs at day 16 were seeded

protocol (Thermo Fisher Scientiﬁc, Waltham, Massa-

(40,000 cells/well) in 150 m l iCell (Stony Brook, New

chusetts). Complementary DNA was synthesized from

York) maintenance medium in 48-well electronic

the pooled RNA (200 ng RNA per sample) by using

microtiter plates (E-Plate Cardio 96, Agilent, Santa

SuperScript

III

Reverse

Transcriptase

(Life
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F I G U R E 1 Study Cohort and CONSORT Diagram

(A) Study cohort: Scatterplot showing the distribution of left ventricular ejection fraction (LVEF) against anthracycline cumulative dose, with
control patients in blue (n ¼ 121), case patients in red (n ¼ 238), and the rest in gray (n ¼ 357). (B) Consolidated Standards of Reporting Trials
(CONSORT) diagram: selection of case and control patients for exome sequencing in the discovery cohort. *Participants with complete data
and good-quality DNA. PCS2 ¼ Preventing Cardiac Sequelae in Pediatric Cancer Survivors.

Technologies, Carlsbad, California). RT-qPCR was

cycles. Relative mRNA expression was quantiﬁed by

performed

pairs

using the 2 –(DDCT) method that calculates the differ-

by

using

different

primer

(Supplemental Table 1). mRNA expression levels were

ences in ﬂuorescence levels at the threshold cycle

normalized to the housekeeping gene, glyceraldehyde

between the target and reference genes (28). Genes

3-phosphate dehydrogenase, and expressed relative

that showed up-regulation following DOX exposure

to the reference group. SYBR GreenER qPCR SuperMix

were prioritized for drug testing. Experiments were

(Thermo Fisher Scientiﬁc, Waltham, Massachusetts)

performed with 3 independent biological replicates,

was used for transcription and ampliﬁcation (ViiA7

each containing 3 technical replicates.

qPCR system, Applied Biosystems, Waltham, Massa-

D r u g t e s t i n g . To determine the effect of target gene

chusetts) by using a total volume of 12 m l and 40 2-step

inhibition on DOX-induced cardiotoxicity, CMs were
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treated with 3 doses of DOX (0.01 m mol/l, 0.1 mmol/l,
and 0.5 m mol/l) with or without 24 h of pre-treatment

T A B L E 1 Clinical Characteristics of the Study Cohort (N ¼ 289)

with 0.1 m mol/l of dimethyl sulfoxide (DMSO) or inhibitors of the protein products. One m mol/l DOX was
associated with cell death and was not used (data not
shown). The DOX doses were consistent with previously

published

studies
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(29,30).

The

inhibitors

Control Patients
(n ¼ 106)

Case Patients
(n ¼ 183)

p Value

57 (53.8)

92 (50.3)

0.566

6.0 (2.0–10.0)

4.0 (2.0–7.0)

0.018

371  115

128  59

<0.001
<0.001

Female
Age at start of anthracycline, yrs
Cumulative anthracycline dose in doxorubicin
equivalent dose, mg/m2

included: 1) dexrazoxane, an iron chelator (Sigma-

Use of dexrazoxane

13 (12.6)

2 (1.1)

Aldrich, St. Louis, Missouri, product no. D1446); 2)

Radiation therapy involving the heart

44 (41.5)

64 (35.0)

TGX-221, a PI3KR2 inhibitor (Selleckchem, Burling-

0.268
<0.001

Cancer diagnosis
Leukemia (AML, ALL)

40 (37.7)

94 (51.4)

0.049

28 (26.4)

2 (1.1)

<0.001

cin, an inhibitor of mammalian target of rapamycin, a

Sarcoma (osteosarcoma, Ewing,
rhabdomyosarcoma)

protein kinase complex downstream of phosphoino-

Neuroblastoma, hepatoblastoma

18 (17.0)

13 (7.1)

0.009

sitide 3-kinase, and (iv) metformin hydrochloride, an

Lymphoma (NHL, HL)

10 (9.4)

35 (19.1)

0.029

2 (1.9)

23 (12.6)

0.002

ton, Ontario, Canada, product no. S1169); 3) rapamy-

inhibitor of TR4, a nuclear receptor involved in zincﬁnger protein, ZNF827, recruitment (Sigma-Aldrich,

Wilms tumor

St. Louis, MO, product no. PHR1084) (31,32). Three

Time from ﬁrst anthracycline dose to
last follow-up echocardiogram, yrs

inhibitor concentrations (0.01 m mol/l, 0.1 m mol/l, and

Duration of treatment, days

1 m mol/l) were studied, and the highest nontoxic dose
was selected similar to published studies (33). All
drugs were prepared in STEMdiff Cardiomyocyte

61.3  6.7

51.7  2.8

<0.001

8.5 (5.0–12.3)

9.0 (6.0–12.3)

0.854

373.3  1,080.5

182.0  282.5

0.026

LVEF at last follow-up, %

Values are n (%), median (interquartile range), or mean  SD.
AML ¼ acute myeloid leukemia; ALL ¼ acute lymphocytic leukemia; HL ¼ Hodgkin lymphoma; LV ¼ left
ventricular; NHL ¼ non-Hodgkin lymphoma.

Maintenance serum-free medium. The half-maximal
inhibitory concentration (IC 50 ) values, that is, the
drug dose required to inhibit a biological process by
50%, were obtained through GraphPad prism 8
(GraphPad Software Inc., San Diego, California) by
using a nonlinear regression analysis function. The
goodness of ﬁt was determined by using coefﬁcient of
determination, R2 .
REPLICATION

COHORT. The

replication

cohort

compare the proportion of discordant pairs between
case versus control patients (i.e., pairs where a case
patient had a variant and the matched control patient
did not, or vice versa). All analyses were performed
by using SAS, version 9.4 (SAS Institute, Inc., Cary,
North Carolina).

comprised a subset of patients with recent enrollment

RANDOM FOREST MODEL FOR RISK PREDICTION.

in the PCS2 study. Patients meeting the clinical deﬁ-

To develop a prediction model for anthracycline car-

nition of cardiotoxicity, that is, LVEF of #50% or

diotoxicity, we developed 3 machine learning algo-

>10% LVEF drop to #55% from a previous echocar-

rithms using clinical factors alone (sex, age at ﬁrst

diogram independent of anthracycline dose, were

anthracycline dose, follow-up duration, the ﬁrst

deﬁned as case patients (15). Control patients were

2 principal components inferring ethnicity, treatment

deﬁned by LVEF >55%. Case and control patients

exposures [i.e., anthracycline dose, use of dexrazox-

were propensity-matched by using a logistic regres-

ane, and chest radiation], genetic factors alone

sion model that included known clinical factors (cu-

(signiﬁcantly associated genes) and a combination of

mulative anthracycline dose, sex, cancer type, age at

clinical and genetic factors. The stratiﬁed boot-

ﬁrst anthracycline dose, follow-up duration, use of

strapping sampling scheme was applied to generate

dexrazoxane, and chest radiation). The propensity

1,000 replicates by using the discovery cohort. Each

score was used to create a 1:1 propensity-matched set

replicate was a pair of independent randomly

by using a greedy algorithm (34). The prioritized

selected training and testing sets with the testing set

genes were sequenced by using targeted exome

corresponding to samples not selected in the training

sequencing in the replication cohort. Exome-enriched

set. A random forest (RF) classiﬁer, based on

libraries were prepared with the Agilent (Santa Clara,

ntree ¼ 500, was applied to each replicate to predict

California) Sureselect XT Custom Kit (1 to 499 kilo

cases with cardiotoxicity based on the 3 models

base pairs, 16 reactions/package) and sequenced on

(clinical, genetic, and combined). RF aggregates the

an Illumina HiSeq4000 (2  100–base pair paired-end

votes from different decision trees to determine the

reads). After collapsing variants within genes, gene

prediction. For each replicate, we trained the RF

association with cardiotoxicity was evaluated using

model in a training set and evaluated the model

burden analysis (chi-square test) and a nonparametric

performance in the testing set. All accuracy measures

test accounting for matched pairs (McNemar test) to

(receiver operator characteristic, area under the curve
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F I G U R E 2 Genes Associated With Anthracycline Cardiotoxicity

(A) A total of 28 genes showed differential enrichment between case and control patients by at least 2 methods (p < 0.001), and 3 additional
biologically relevant genes (orange) were signiﬁcant by at least 1 method. (B) Burden of rare and low-frequency single-nucleotide variants in
the 31 prioritized genes was higher in control patients compared to case patients (p < 0.001). (C) Forest plot showing the estimated odds
ratios (95% conﬁdence intervals) for the 31 top genes in case versus control patients using Fisher exact test. Genes in bold were prioritized
for functional studies.

Continued on the next page

[AUC], sensitivity, speciﬁcity, positive predictive

0.001).

value, negative predictive value (NPV), false positive

anthracycline dose, case patients had a higher fre-

Concordant

with

a

lower

cumulative

rate, false negative rate] and misclassiﬁcation rates

quency of Wilms tumor (p ¼ 0.002) and were less

were compared over 1,000 replicates, and observed

likely to have received dexrazoxane (p < 0.001). No

versus predicted case status was calculated with 0.5

sex-based differences were observed between case

probability cutoff for each replicate. Within each

and control patients.

replicate, accuracy measures and misclassiﬁcation
rates were estimated in the training set and the
testing set. The overall accuracy measure was the
sum of the accuracy measures and the misclassiﬁcation rates from the training set and the paired testing
set, weighted by 0.368 and 0.632, respectively. This
was repeated for all 3 RF models.

VARIANTS IDENTIFIED ON EXOME SEQUENCING.

Average sequencing coverage was 99 (range: 69 to
234). A total of 9,092,459 SNVs were identiﬁed. After excluding common variants (MAF: >0.05), we
identiﬁed

110,558

rare/low-frequency

non-

synonymous SNVs in 17,382 unique genes in the
cohort. Principal component analysis was performed
by using 332,033 common SNVs (MAF: >0.01 in

RESULTS

Genome Aggregation Database) mapped to HapMap to
COHORT CHARACTERISTICS. A total of 716 partici-

ascertain the distribution of ethnicity in the study

pants enrolled in the PCS2 study met eligibility

cohort (Supplemental Figure 1).

criteria. The discovery cohort for exome sequencing

GENE-ASSOCIATION

included 289 participants, including 183 case and

variants within genes, we identiﬁed 48 unique genes

ANALYSIS. After

collapsing

106 control patients (Figure 1). Clinical characteris-

associated with cardiotoxicity—29 genes by burden

tics are shown in Table 1. Case patients were

combined multivariate and collapsing, 25 genes by

younger

therapy

SKAT, and 29 genes by SKAT-optimized (p < 0.001).

(p ¼ 0.012), but follow-up duration was not different

No single gene reached exome-wide signiﬁcance

between case and control patients. As expected

(Supplemental Figures 2 and 3). Of the 48 genes, 28

from the selection criteria, the LVEF and the cu-

showed differential enrichment by at least 2 methods

mulative anthracycline dose were lower in case pa-

(p < 0.001), and 3 additional genes previously impli-

at

the

time

of

anthracycline

tients compared to control patients (p < 0.001). The

cated in cardiotoxicity were identiﬁed by at least 1

duration of treatment was correlated with cumula-

method (p < 0.001) (Figures 2A and 2B, Supplemental

tive anthracycline dose (Spearman rho: 0.54; p <

Tables 2 and 3). Variant burden analysis showed that
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F I G U R E 3 Pathways Associated With Anthracycline Cardiotoxicity

(A) GeneMania analysis identiﬁed 46 interacting genes, including 26 of the 31 top genes. Large circles represent signiﬁcantly associated
genes; small circles represent other interacting genes. Physical interaction (pink lines), coexpression (purple lines), colocalization (blue
lines), shared protein domains (gray-yellow lines), genetic interaction (green lines), and predicted (orange lines). (B) Gene set enrichment
analysis identiﬁed the top-ranked pathways to which the genes mapped (p < 0.001). The solid bar shows number of signiﬁcant genes in each
pathway (p < 0.001); the dashed bar represents the total genes.
Continued on the next page

fewer case patients (42.6%) compared to control pa-

echocardiogram, the variant burden remained lower

tients (89.6%) harbored a variant in these 31 genes

in the case patients (42.3%) compared to the control

(OR: 0.09; 95% CI: 0.04 to 0.17; p ¼ 3.98  10–15 )

patients (89.6%) (OR: 0.08; 95% CI: 0.04 to 0.18;

(Figure 2C). Frequency of multiple variants was also

p ¼ 5.46  10–12). In subgroup analysis of 80 case

lower in case patients (21%) compared to control pa-

patients and 63 control patients with self-reported

tients (71%) (OR: 0.11; 95% CI: 0.06 to 0.19; p ¼ 4.74 

White ethnicity, variant burden was again lower in

10–17). In a subset of 78 cases limited to LVEF of #50%

case patients (72%) compared to control patients

or >10% LVEF decline to #55% from a previous

(89%) (OR: 0.33; 95% CI: 0.13 to 0.83; p ¼ 0.019).
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F I G U R E 3 Continued

Therefore, absence of these protective variants was

cells (p ¼ 0.039) (Figures 4C and 4D). DOX treatment

associated with risk of anthracycline cardiotoxicity.

up-regulated

Logistic regression adjusted for anthracycline dose

(p ¼ 0.001), ELAC2 (p ¼ 0.012), and PI3KR2

and the use of concomitant cardiotoxic agents

(p ¼ 0.016) compared to DMSO but did not change

showed that the 31 genes remained signiﬁcant with

SEC62 and USP42 mRNA expression (Figure 5A).

similar ORs in unadjusted and adjusted analyses

Based on the availability of targeted inhibitors, we

(Supplemental Table 4).

selected PI3KR2 and ZNF827 for further study.

GENE CHARACTERIZATION AND PATHWAY ANALYSIS.

Target gene inhibition prevented DOX-induced

The functions of the 31 prioritized genes are sum-

c a r d i o t o x i c i t y . iPSC-CMs

marized in Supplemental Table 5. Most genes

dividuals were pre-treated for 24 h before DOX

belonged to the PI3K/AKT/mTOR pathway and p53

exposure with either a nontargeted inhibitor, dexra-

signaling pathways. The PI3K pathway was also 1 of

zoxane (iron chelator), or with targeted inhibitors:

the 6 pathways showing differential enrichment

TGX-221 (PI3KR2 inhibitor), rapamycin (mTOR inhib-

between case and control patients using GeneMania

itor downstream of PI3KR2), or metformin (ZNF827

(Figures 3A and 3B). ZNF827, ELAC2, SEC62, USP42,

inhibitor) (Supplemental Table 6). Dose-response

and PIK3R2 were selected for functional analysis

curves of DOX-induced decrease in CM viability

mRNA

expression

from

2

of

ZNF827

healthy

in-

based on 1 or more of the following additional criteria:

were generated, and the IC 50 values for DOX (i.e., the

biological relevance, protein expression in the human

dose of DOX that causes a 50% decrease in viability)

heart (Supplemental Table 5), and mRNA expression

were determined (Figures 5B and 5C). The goodness of

in hiPSC-CMs.

ﬁt R 2 values were >0.9 for all IC50 curves. A higher
hiPSC-CMs. D O X

IC 50 indicates lower drug potency or need for a higher

decreased CM viability and increased ZNF827,

drug dose to cause 50% target effect. The IC 50 values

ELAC2,

FUNCTIONAL

EVALUATION

PI3KR2

IN

24-hour

(95% CI) of DOX demonstrated that targeted in-

treatment with DOX resulted in a dose-dependent

hibitors, TGX-221 and metformin, were effective at

decrease in cell index in hiPSC-CMs (Figure 4A), as

blocking DOX-induced decrease in CM viability in

well as in metabolic activity and proliferation

both lines. Metformin was superior in its car-

(Figure 4B). Treatment with 0.1 mmol/l DOX caused

dioprotective effect compared to dexrazoxane in both

an increase in g -H2AX nuclear foci, a marker of

lines, and TGX-221 was superior in PGP17 and com-

double-stranded DNA breaks, compared to untreated

parable to dexrazoxane in PGP14 (Table 2). Therefore,

and

expression. A
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F I G U R E 4 Effect of Anthracycline in hiPSC-CMs

(A) The 24-h DOX treatment caused a dose-dependent decrease in cell function and viability in hiPSC-CMs measured using the cell index. (B) Presto blue cell viability
assay demonstrated a decrease in metabolic activity and proliferation with increasing DOX doses. The values represent the average relative ﬂuorescence from 3 independent experiments. (C) Representative immunoﬂuorescence images showing increased g-H2AX staining (green) (white arrow), a DNA damage marker, in the nuclei
(blue DAPI staining) of DOX-treated cells. (D) DOX treatment increased average g-H2AX foci per nucleus compared to untreated cells. Error bars represent mean  SD
for 3 independent biological replicates. *p < 0.05; ***p < 0.001. CMC ¼ combined multivariate and collapsing; DAPI ¼ 40 ,6-diamidino-2-phenylindole;
DMSO ¼ dimethyl sulfoxide; DOX ¼ doxorubicin; H2AX ¼ H2A family member X; hiPSC-CM ¼ human induced pluripotent stem cell–derived cardiomyocyte;

mM ¼ mmol/l.

pharmacologic disruption of gene-associated path-

number of discordant pairs (n ¼ 10). Although not

ways was cardioprotective, similar to the presence of

statistically signiﬁcant (p ¼ 0.114), 8 of the 10 pairs

putatively

involved variants present in control patients but ab-

disruptive

genetic

variants

in

these

pathways.
REPLICATION

sent in case patients. This difference was nominally
OF

FUNCTIONALLY

VALIDATED

signiﬁcant

on

conditional

logistic

regression

GENES. Variant burden in the top 2 genes, PI3KR2

(p ¼ 0.08). No test could be performed for 11 genes

and ZNF827, was compared between 30 case patients

that did not harbor variants in the replication cohort,

and 30 propensity-matched control patients in the

which reduced our power to detect discordant pairs.

replication cohort (Supplemental Table 7). There was

A comparison of variants in ZNF827 could not be

a lower variant burden in PI3KR2 in case patients

performed because only 2.4% of the cohort harbored

(6.7%) compared to control patients (26.7%) (OR:

a variant, all of which were in control patients.

0.196; 95% CI: 0.038 to 1.02; p ¼ 0.038). McNemar test

RF RISK PREDICTION MODELING. We trained 3 RF

identiﬁed PIK3R2 as the gene with the highest

prediction models in a training set and evaluated
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F I G U R E 5 Effect of Targeted Gene Inhibition on DOX-Induced Cardiotoxicity in hiPSC-CMs

(A) RT-qPCR analysis of PGP17 hiPSC-CMs (3 biological replicates, each containing 3 technical replicates) treated with 0.1 mmol/L DOX
demonstrated a signiﬁcant increase in gene expression levels of ZNF827, ELAC2, and PI3KR2. (B) PGP17 and (C) PGP14 hiPSC-CMs were pretreated with DMSO or an inhibitor for 24 h and then exposed to DOX for 24 h. Dose-response curves for cell index, that is, CM viability, and
IC50 values for DOX with and without inhibitors are shown. Data are mean  SD for 3 independent replicates. *p < 0.05; **p < 0.01.
PGP ¼ Personal Genome Project; RT-qPCR ¼ quantitative reverse transcription polymerase chain reaction; other abbreviations as in
Figure 4.

their performance in the testing and overall set

DISCUSSION

(Table 3). We chose a random resampling approach,
which is superior to a training/validation split in

Despite dose-dependent anthracycline cardiotoxicity,

the absence of an external validation cohort. Box-

only a proportion of patients who receive high-dose

plots of the accuracy measures are shown in

anthracycline develop cardiotoxicity (35). Our ﬁnd-

Figures 6A to 6C. The clinical RF model had the

ings showed that almost 90% of patients without

lowest performance across all accuracy measures

cardiotoxicity harbored rare/low-frequency variants

and higher misclassiﬁcation rate compared to the

in cardiac injury pathways that likely protected them

genetic and combined models. The performance

from the damaging effects of anthracycline. In

metrics of the 3 models in the training set, the

contrast,

testing set, and overall dataset are shown in

harbored these protective variants. The resistance to

Table 3. In the testing set, the AUC for the clinical

cardiotoxicity with disruption of these pathways was

model was 0.59 (95% CI: 0.51 to 0.67), for the ge-

conﬁrmed through pharmacological inhibition of the

netic model was 0.71 (95% CI: 0.63 to 0.80), and

pathways in human CMs. Using these genetic ﬁndings

for the combined model was 0.72 (95% CI: 0.63 to

in combination with clinical risk predictors, we

0.80)

out-

developed and internally validated a prediction

performed the clinical model with a higher AUC,

model and demonstrated its superiority to the clinical

higher speciﬁcity, higher positive predictive value,

model in predicting cardiotoxicity. Furthermore, we

and a lower misclassiﬁcation rate.

identiﬁed

(Figure

6D).

The

combined

model

<50%

of

patients

potentially

with

druggable

cardiotoxicity

pathways

of
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T A B L E 2 IC 50 Values (95% CI) of DOX and Inhibitors in hiPSC-CMs Derived From PGP17

and PGP14 Individuals

common variants associated with anthracycline cardiotoxicity, often in pharmacokinetic genes, that account for a relatively small proportion of cases (10).

PGP17_11

PGP14_26

p Value vs. DOX

IC50

IC50

Often these studies did not account for clinical and

p Value vs. DOX

0.21 (0.14–0.31)

treatment differences, differences in anthracycline

Doxorubicin

0.09 (0.04–0.16)

TGX-221

0.71 (0.51–0.98)

0.045

0.49 (0.33–0.72)

0.043

Metformin

0.58 (0.43–0.78)

0.017

0.98 (0.56–1.80)

0.039

Rapamycin

0.26 (0.14–0.44)

0.178

0.26 (0.17–0.39)

0.164

extreme phenotype approach stratiﬁed by anthracy-

Dexrazoxane

0.22 (0.15–0.33)

0.077

0.61 (0.43–0.88)

0.047

cline dose was to enrich our cohort for rare and low-

dose, or differences in follow-up between case and
control patients. An important rationale for an

frequency variants that are expected to have a
CI ¼ conﬁdence interval; DOX ¼ doxorubicin; hiPSC-CMs ¼ human induced pluripotent stem cell-derived cardiomyocytes; IC50 ¼ half-maximal inhibitory concentration; PGP ¼ Personal Genome Project.

stronger effect on phenotype rather than only common variants. An extreme phenotype design is superior to a simple case-control design for detecting

cardiotoxicity that may offer better cardioprotection

rare risk variants, especially protective variants (36).

than currently available drugs like dexrazoxane. A

To minimize bias related to an imbalance in cancer

strength of our study was its prospective longitudinal

types between case and control patients, we excluded

design with adjustment for length of follow-up,

cancer-causing variants and adjusted our analysis for

which minimized potential misclassiﬁcation of case

cancer diagnosis.

and control patients, as well as conﬁrmation of our

Of the differentially enriched genes in our study,

ﬁndings through functional validation and replica-

only CELF4 has been previously reported as a car-

tion studies.

diotoxicity gene in human studies (8,37). ZNF827 and
PI3KR2, which demonstrated a higher variant burden

RARE VARIANT CONTRIBUTION TO ANTHRACYCLINE

in control patients compared to case patients, are

CARDIOTOXICITY. Previous

poly-

involved in autophagy, a pathway known to be

identiﬁed

involved in anthracycline cardiotoxicity and cardio-

morphism

association

single-nucleotide
studies

have

vascular disease. PI3KR2 encodes the p85b isoform, a
T A B L E 3 Accuracy Measures for Prediction Models of Anthracycline Cardiotoxicity

regulatory subunit involved in autophagy inhibition
through the phosphoinositide dependent kinase-1

Accuracy
Measure

Dataset

Clinical Model

Genetic Model

Combined Clinical
and Genetic Model

AUC

Training

0.9990  0.0026

0.8996  0.0216

0.9923  0.0063

Although we did not measure autophagy, we did ﬁnd

Testing

0.5896  0.0431

0.7133  0.042

0.7156  0.0421

0.7403  0.0273

0.7819  0.0262

0.8174  0.0267

PI3KR2 up-regulation and accumulation of DNA

Overall
Training

0.9980  0.0053

0.8232  0.0457

0.9846  0.0127

Testing

0.4317  0.0885

0.5552  0.0827

0.5254  0.0836

Overall

0.6401  0.056

0.6538  0.054

0.6944  0.0528

Training

1.0000  0.0004

0.9760  0.0168

0.9999  0.0008

Sn

Sp

PPV

NPV

MC

FPR

FNR

and

protein

kinase

B

signaling

pathway

(38).

damage with DOX that may be related to impaired
autophagy-mediated DNA repair (39). TGX-221, a selective inhibitor of PI3KR2, yielded a greater cardioprotective

effect

against

DOX

compared

to

Testing

0.7475  0.0682

0.8715  0.0513

0.9057  0.047

dexrazoxane, an iron chelator. Importantly, preclini-

Overall

0.8404  0.0431

0.9100  0.035

0.9404  0.0297

cal tumor studies have reported that PI3KR2 inhibi-

Training

1.0000  0.0005

0.9609  0.0254

0.9999  0.0011

tion

Testing

0.4885  0.0749

0.7259  0.0820

0.7623  0.0942

targeting PI3KR2 could mediate a cardioprotective

reduces

tumorigenicity,

suggesting

that

Overall

0.6767  0.0473

0.8124  0.0544

0.8498  0.0595

Training

0.9986  0.0035

0.8893  0.0253

0.9896  0.0084

Testing

0.7058  0.0384

0.7684  0.0376

0.777  0.0365

Overall

0.8135  0.0243

0.8129  0.0239

0.8552  0.0231

Training

0.0008  0.0021

0.0864  0.0182

0.0063  0.0051

anthracycline cardiotoxicity through enrichment of

Testing

0.3652  0.0423

0.2465  0.0385

0.2297  0.0373

variants

Overall

0.2311  0.0268

0.1876  0.0241

0.1475  0.0237

expression on DOX exposure in CMs, and protection

Training

0.0000  0.0002

0.0141  0.0098

0.0000  0.0005

against DOX cardiotoxicity with metformin. Metfor-

Testing

0.1632  0.0457

0.0807  0.0325

0.0610  0.0308

0.1032  0.0289

0.0562  0.0220

0.0386  0.0195

min, involved in 5 0 adenosine monophosphate–acti-

Overall
Training

0.0008  0.0021

0.0723  0.0185

0.0063  0.0051

Testing

0.2020  0.0365

0.1658  0.0333

0.1687  0.0334

Overall

0.1279  0.0231

0.1314  0.0215

0.1089  0.0211

effect without being tumor protective, one of the
main concerns with the use of dexrazoxane (40,41).
We also noted an important role for ZNF827 in

vated

in

control

protein

kinase

patients,

signaling,

increased

mRNA

suppresses

the

activation of the nuclear receptor TR4, which in turn
inhibits the recruitment of ZNF827 and consequently
induces cardiac autophagy. Studies have demon-

Values are mean  SD.

strated a cardioprotective effect of metformin in

AUC ¼ area under the curve; FNR ¼ false negative rate; FPR ¼ false positive rate; MC ¼ misclassiﬁcation;
NPV ¼ negative predictive value; PPV ¼ positive predictive value; Sn ¼ sensitivity; Sp ¼ speciﬁcity.

DOX-induced cardiotoxicity in rats through normalized autophagy processes (32). Our ﬁnding of the
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F I G U R E 6 Accuracy Measures of Prediction Models Using Random Forest

Boxplots representing the accuracy measures for the overall dataset, the testing set, and the training set for the (A) clinical model, (B) genetic model, (C) combined
model, and (D) receiver operator characteristic AUC for model-derived prediction of anthracycline cardiotoxicity. Clinical model AUC: 0.59 (black), genetic model AUC:
0.71 (blue), combined model AUC: 0.72 (red). AUC ¼ area under the curve; FNR ¼ false negative rate; FPR ¼ false positive rate; MC ¼ misclassiﬁcation; NPV ¼ negative
predictive value; PPV ¼ positive predictive value; Sens ¼ sensitivity; Sn ¼ sensitivity; Sp ¼ speciﬁcity; Spec ¼ speciﬁcity.

Continued on the next page

cardioprotective effect of metformin, an antidiabetic

MACHINE

drug, in human CMs suggests a promising potential

MODELING. An important outcome of our study was

LEARNING

IN

RISK

PREDICTION

for drug repurposing of metformin for protection

the development of a prediction model for anthracy-

against anthracycline cardiotoxicity.

cline cardiotoxicity using a combination of genetic
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F I G U R E 6 Continued

and clinical factors that outperformed the clinical

individuals with high conﬁdence in whom the modi-

model. In particular, the combined model had high

ﬁcation of chemotherapy or use of cardioprotective

speciﬁcity, good sensitivity, and a low misclassiﬁca-

agents could be justiﬁed. By avoiding overestimation

tion rate. Although this model is exploratory and re-

of the risk of anthracycline cardiotoxicity, it would

quires

prevent withholding life-saving anthracycline in pa-

external

validation,

a

model

with

high

speciﬁcity is desirable for the identiﬁcation of at-risk

tients who are not at high risk.
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CONCLUSIONS
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Childhood cancer survivors with rare variants in
genes involved in cardiac injury pathways have a
lower susceptibility to anthracycline cardiotoxicity.
Incorporating these genetic factors into a prediction
model helped identify individuals at lower risk
for anthracycline cardiotoxicity with high speciﬁcity.
This knowledge may be useful in the future to
individualize
tailored

to

anthracycline-based
a

patient’s

risk

chemotherapy

for

cardiotoxicity.

The identiﬁcation of promising biological targets
involved in autophagy (PI3KR2 and ZNF827) will
inform the development and/or repurposing of cardioprotective agents in patients receiving anthracyclines. Thus, our study shows the power of a precision
approach in informing strategies for tailored man-

PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Childhood cancer survivors harboring rare variants in pathways of cardiac injury
are protected from anthracycline cardiotoxicity. A prediction
model for anthracycline cardiotoxicity that combines clinical and
genetic risk factors performs better than a clinical model.
TRANSLATIONAL OUTLOOK: External validation of the risk
prediction model is needed to inform its use as a clinical decision
support tool for tailoring anthracycline chemotherapy to individual risk. The identiﬁed genes suggest novel biological pathways for development of cardioprotective agents.

agement of childhood cancer patients.
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